1. Academic Validation
  2. Uncovering the key pharmacodynamic material basis and possible molecular mechanism of Xiaoke formulation improve insulin resistant through a comprehensive investigation

Uncovering the key pharmacodynamic material basis and possible molecular mechanism of Xiaoke formulation improve insulin resistant through a comprehensive investigation

  • J Ethnopharmacol. 2024 Jan 10:117752. doi: 10.1016/j.jep.2024.117752.
Wenjuan Ma 1 Jianglan Long 2 Linjie Dong 1 Jian Zhang 3 Aiting Wang 2 Yu Zhang 4 Dan Yan 5
Affiliations

Affiliations

  • 1 School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Benxi, Liaoning, 110016, China.
  • 2 Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China.
  • 3 College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
  • 4 Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. Electronic address: zhangyuddnh@163.com.
  • 5 Beijing Institute of Clinical Pharmacy, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China. Electronic address: anyan@ccmu.edu.cn.
Abstract

Ethnopharmacological relevance: Xiaoke formulation (XKF) has been utilized in clinical practice for decades in China as a treatment option for mild to moderate type 2 diabetes. However, there is still a need for systematic research to uncover the key pharmacodynamic material basis and mechanism of XKF.

Aim of the study: Aim of to investigate the distribution and metabolism of XKF in normal and Insulin resistant (IR) mice were different, and elucidate its key pharmacodynamic material basis and mechanism of action.

Materials and methods: Ultra performance liquid chromatography/time of flight mass spectrometry technology was employed to investigate the differences in XKF absorption, distribution, and metabolism between normal and IR mice across blood, liver, feces, and urine samples. Further, network pharmacology was used to predict target proteins and their associated signaling pathways. Then, molecular docking was utilized to validate the activity of key pharmacodynamic components and targets. Finally, IR HepG2 cells were used to detect the glucose consumption under the action of key pharmacodynamic material basis. In addition, the expression of phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt) and phospho-protein kinase B (p-AKT) was determined using western blotting.

Results: The study demonstrates significant distinctions in plasma and liver number and abundance of Alkaloids, organic acids, Flavonoids, Iridoids and saponins between normal and IR mice when XKF was administered. Further analysis has shown that the representative components of XKF, including berberine, chlorogenic acid, calycosin, swertiamarin and astragaloside IV have significantly different metabolic pathways in plasma and liver. Prototypes and metabolites of these components were rarely detected in the urine and faeces of mice. According to the network pharmacological analysis, these differential components are predicted to improve IR by targeting key factors such as Src, JUN, HRAS, NOS3, FGF2, etc. Additionally, the signaling pathways involved in this process include PI3K-AKT pathway, GnRH signaling pathway, and T cell receptor signaling pathway. In addition, in vitro experiments indicate that berberine and its metabolites (berberine and demethyleneberine), chlorogenic acid and its metabolites (3-O-ferulic quinic acid and 5-O-ferulic quinic acid), calycosin and swertiamarin could improve IR in IR-HepG2 cells by elevating the expression of PI3K and Akt, leading to an increase in glucose consumption.

Conclusion: The key pharmacodynamic material basis of XKF, such as berberine and its metabolites (berberrubine and demethyleneberberine), chlorogenic acid and its metabolites (3-O-feruloylquinic acid and 5-O-feruloylquinic acid), calycosin and swertiamarin influence the glucose metabolism disorder of IR-HepG2 cells by regulating the PI3K/Akt signalling pathway, leading to an improvement in IR.

Keywords

Insulin resistance; Key pharmacodynamic material basis; Metabolic transformation; Network pharmacology; PI3K/AKT signaling pathway; Xiaoke formulation.

Figures
Products